perindopril + indapamida zentiva 4 mg + 1.25 mg comprimido
zentiva portugal, lda. - perindopril + indapamida - comprimido - 4 mg + 1.25 mg - indapamida 1.25 mg ; perindopril, tert-butilamina 4 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida tolife 2 mg + 0.625 mg comprimido
towa pharmaceutical, s.a. - perindopril + indapamida - comprimido - 2 mg + 0.625 mg - indapamida 0.625 mg ; perindopril, tert-butilamina 2 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida vitória 4 mg + 1.25 mg comprimido
faes farma portugal, s.a. - perindopril + indapamida - comprimido - 4 mg + 1.25 mg - indapamida 1.25 mg ; perindopril, tert-butilamina 4 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida vitória 2 mg + 0.625 mg comprimido
faes farma portugal, s.a. - perindopril + indapamida - comprimido - 2 mg + 0.625 mg - indapamida 0.625 mg ; perindopril, tert-butilamina 2 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida vitória 2 mg + 0.625 mg comprimido
faes farma portugal, s.a. - perindopril + indapamida - comprimido - 2 mg + 0.625 mg - indapamida 0.625 mg ; perindopril, tert-butilamina 2 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida vitória 2 mg + 0.625 mg comprimido
faes farma portugal, s.a. - perindopril + indapamida - comprimido - 2 mg + 0.625 mg - indapamida 0.625 mg ; perindopril, tert-butilamina 2 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
perindopril + indapamida vitória 2 mg + 0.625 mg comprimido
faes farma portugal, s.a. - perindopril + indapamida - comprimido - 2 mg + 0.625 mg - indapamida 0.625 mg ; perindopril, tert-butilamina 2 mg - perindopril and diuretics - genérico - duração do tratamento: longa duração
lonsurf
les laboratoires servier - trifluridine, tipiracil cloridrato de - neoplasias colorretais - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
gladexa 30 mg cápsula de libertação modificada
takeda - farmacêuticos portugal, lda. - dexlansoprazol - cápsula de libertação modificada - 30 mg - dexlansoprazol 30 mg - dexlansoprazole - n/a - duração do tratamento: longa duração
gladexa 60 mg cápsula de libertação modificada
takeda - farmacêuticos portugal, lda. - dexlansoprazol - cápsula de libertação modificada - 60 mg - dexlansoprazol 60 mg - dexlansoprazole - n/a - duração do tratamento: longa duração